I was flicking through the SUSMP and noticed Appendix K, a list of drugs that are required to have a sedation warning. I noticed that vintage compounds, such as meprobamate, are included, yet the drug sodium oxybate is missing from this list. I presume this is an oversight, as had its more commonly known name, hadGHB, been used -- GHB, perhaps the matter would be viewed a little differently.

To put it in context: a drug whosewith subjective effects that could be described as sleep personified is missing from Appendix K, yet agents with minimal sedating effects have beenare included. It is prudent to note that this is not a tangential point I am making -- although. Although GHB is a controlled substance, it is marketed as sodium oxybate in the US as a treatment offor several sleep disorders. It is entirely possible that it has been, or will eventually be, imported into Australia under the Special Access Scheme.

In light of this, I was hoping to make a public submission for consideration. However, the template you provide is considerably lengthy, given the nature of the amendment I am proposing. It is also unclear to me if this is meant for the public.